PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 1, 2024ESMO OpenOpen Access

27O Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRocio García‐CarboneroGCGregory A. CotéACA. Le Cesne

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

García‐Carbonero et al. (2024) studied this question.

synapsesocial.com/papers/68e76923b6db6435876dece8https://doi.org/10.1016/j.esmoop.2024.102416
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort2026
  2. 2Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors2025 · 3 citations
  3. 3Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.2026
  4. 4Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.2024 · 2 citations
  5. 5A phase I/II study of nanoliposomal irinotecan and carboplatin in patients with advanced or metastatic, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma characterized by tissue and liquid next-generation sequencing.2024